Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-9-18
pubmed:abstractText
We previously showed that the expression of p16(ink4a) (p16), in conjunction with retinoic acid (RA) treatment in the p16-deficient astrocytoma cell line, U343 MG-A, induced a potent cell cycle arrest in G(1) associated with changes in morphology. In this study, we investigated the effects of p16 expression and RA treatment on the expression and distribution of actin, glial fibrillary acidic protein (GFAP), and vimentin within the U343 MG-A astrocytoma cytoskeleton. Changes in expression and location of the small GTPase, rhoA, were also examined after p16 expression and RA treatment. We showed that p16 expression and RA treatment led to an increase in the expression of GFAP, as well as its reorganization but that it did not significantly affect actin or vimentin expression. p16 induction in combination with RA treatment resulted in a decreased expression and activation of rhoA as determined by immunocytochemistry and Western blot analysis of soluble and insoluble fractions of cell lysates. Endogenous levels of rhoA expression varied among samples in a panel of astrocytoma cell lines as determined by Western blot analysis. Introduction of a dominant active rhoA mutant into p16-induced, RA-treated U343 MG-A astrocytoma cells was associated with the loss of long astrocytic processes and stellate morphology. These data are among the first to report the pattern of rhoA expression in human astrocytoma cell lines. They furthermore suggest that the stellate cell phenotype observed in U343 MG-A astrocytoma cells after cyclin-dependent kinase inhibitor (CKI) induction and RA treatment is accompanied by an inhibition and inactivation of rhoA in this cell system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0894-1491
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
85-94
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12237846-Actin Cytoskeleton, pubmed-meshheading:12237846-Astrocytoma, pubmed-meshheading:12237846-Brain Neoplasms, pubmed-meshheading:12237846-Cell Compartmentation, pubmed-meshheading:12237846-Cell Differentiation, pubmed-meshheading:12237846-Cell Membrane, pubmed-meshheading:12237846-Cell Movement, pubmed-meshheading:12237846-Cell Size, pubmed-meshheading:12237846-Cell Transformation, Neoplastic, pubmed-meshheading:12237846-Cyclin-Dependent Kinase Inhibitor p16, pubmed-meshheading:12237846-Gene Expression Regulation, Neoplastic, pubmed-meshheading:12237846-Glial Fibrillary Acidic Protein, pubmed-meshheading:12237846-Humans, pubmed-meshheading:12237846-Immunohistochemistry, pubmed-meshheading:12237846-Phenotype, pubmed-meshheading:12237846-Protein Transport, pubmed-meshheading:12237846-Tretinoin, pubmed-meshheading:12237846-Tumor Cells, Cultured, pubmed-meshheading:12237846-rhoA GTP-Binding Protein
pubmed:year
2002
pubmed:articleTitle
p16(ink4a) and retinoic acid modulate rhoA and GFAP expression during induction of a stellate phenotype in U343 MG-A astrocytoma cells.
pubmed:affiliation
Arthur and Sonia Labatt Brain Tumour Research Centre, and Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't